Can COVID-19 Cause Irritable Bowel Syndrome (IBS)?

COVID-19 does appear capable of triggering irritable bowel syndrome, and the link is strong enough that researchers have given it a name: post-COVID IBS, a subset of the broader category known as post-infectious IBS. Pooled data from multiple studies put the rate at roughly one in ten COVID-19 patients developing IBS symptoms in the months following infection, though the exact numbers and the strength of the association vary depending on the study design and how long researchers follow patients.

How Common Is Post-COVID IBS?

Several systematic reviews and meta-analyses have tried to pin down how often IBS develops after a bout of COVID-19, and their estimates cluster in a similar range but differ in important details. One meta-analysis pooling ten studies reported a 12% incidence of IBS among COVID-19 patients, with diarrhea-predominant IBS being the most common subtype at about 5%, followed by constipation-predominant at 2% and mixed-type at 1%.¹ A separate meta-analysis that included nearly 4,000 COVID-19 patients and about 1,000 controls found a lower overall rate of 7.2% in COVID patients versus 4.9% in healthy controls, with COVID patients roughly two and a half times more likely to develop IBS.²

A smaller single-center study from India found that about 10.6% of COVID-19 patients developed new IBS, with diarrhea-predominant IBS accounting for over half of those cases.³ And in one case-control study using the stricter Rome IV diagnostic criteria, 3.2% of COVID patients met the threshold for IBS compared with just 0.5% of controls.⁴

The spread in these numbers reflects real differences in study populations, follow-up time, and diagnostic criteria. One telling pattern: the pooled incidence at six months was around 10%, but by twelve months it had dropped to about 3%.¹ That decline suggests many cases resolve over time, though a meaningful fraction of patients are left with chronic symptoms.

How COVID-19 Compares to Other Gut Infections

Post-infectious IBS is not a new concept. Gastroenterologists have recognized for decades that bacterial infections with organisms like Campylobacter and Salmonella can leave patients with lasting IBS symptoms long after the bacteria themselves are cleared. What surprised researchers early in the pandemic was that a respiratory virus could do the same thing. A large systematic review comparing different infectious triggers found that Campylobacter was associated with the highest raw prevalence of post-infectious IBS at about 21%, but SARS-CoV-2 was tied for the highest odds ratio at 5.4, matching Proteobacteria.⁵ In other words, while more people develop IBS after classic food-poisoning bugs in absolute terms, the relative risk jump after COVID-19 compared to uninfected controls is among the largest observed.

This comparison matters because it places COVID-19 firmly within a recognized pattern. The gut has well-documented vulnerability to infection-triggered functional disorders, and SARS-CoV-2 exploits that vulnerability through mechanisms that overlap with, but are not identical to, those seen in bacterial infections.

Why a Respiratory Virus Affects the Gut

The reason COVID-19 can trigger bowel problems begins with a basic anatomical fact: the cells lining your intestines carry the same molecular doorway the virus uses to enter lung cells. SARS-CoV-2 binds to a receptor called ACE2 and relies on a protein called TMPRSS2 to get inside cells. Both are abundant on gut enterocytes, which means the virus can directly infect the intestinal lining.⁶ This is not just theoretical; patients with COVID-19 shed viral RNA in stool, and researchers have observed direct viral infection of intestinal tissue.

But what turns a temporary gut infection into a chronic functional disorder? The answer involves several overlapping processes, and teasing them apart is an area of active research.

The Virus That Lingers

One of the most striking findings in post-COVID gut research is how long the virus, or at least fragments of it, can persist in intestinal tissue. In a study of patients with long COVID, researchers found SARS-CoV-2 spike protein RNA in the rectosigmoid tissue of all five participants tested, with some samples collected up to 676 days after their initial infection. Three of those five had double-stranded RNA, which suggests the virus was not just leftover debris but may have been actively copying itself at some level.⁷

A separate investigation by Zollner and colleagues found that about 70% of participants harbored SARS-CoV-2 RNA in intestinal mucosal tissue roughly seven months after infection, and 52% had viral protein in the intestinal lining. The persistence was not related to how severe the original illness had been but was associated with ongoing long COVID symptoms.⁸ This suggests the gut may act as a viral reservoir, keeping the immune system in a state of low-level activation long after the acute respiratory illness has resolved.

In people with long COVID, this persistent viral material appears to drive localized immune problems. One study examining gut biopsies from long COVID patients found increased mast cell activity and elevated levels of zonulin, a marker of compromised gut barrier function, alongside persistent viral nucleocapsid protein in the terminal ileum.⁹ A leaky gut barrier lets molecules pass into surrounding tissue that normally would not, provoking ongoing immune responses and contributing to the abdominal pain, bloating, and altered bowel habits that define IBS.

How COVID-19 Reshapes the Gut Microbiome

The trillions of bacteria in your gut produce short-chain fatty acids, molecules that feed the cells lining the intestine, regulate immune responses, and influence how the gut moves food along. COVID-19 disrupts this microbial ecosystem in ways that persist well beyond the acute illness. A study published in Gastroenterology found that patients with COVID-19, especially those with severe disease, showed significant depletion of the bacterial groups responsible for producing short-chain fatty acids and the amino acid L-isoleucine. Those deficits were still detectable more than 30 days after recovery, and lower levels of these metabolites correlated with higher markers of systemic inflammation.¹⁰

This matters for IBS because short-chain fatty acid depletion is a feature researchers already see in conventional IBS patients. When those molecules are in short supply, the gut lining becomes more permeable, immune cells become more reactive, and intestinal motility can shift in unpredictable ways. COVID-19 essentially recreates conditions that are known to sustain IBS-type symptoms.

Serotonin and the Gut-Brain Axis

Most people associate serotonin with mood, but about 95% of the body’s serotonin is made in the gut, primarily by specialized enterochromaffin cells. These cells turn out to be uniquely vulnerable to SARS-CoV-2 because they express the key viral entry genes at higher levels than other intestinal cell types.¹¹ When the virus infects these cells, it can alter serotonin production and release, which affects both gut motility and the signaling between the gut and the brain.

Researchers have found that patients with persistent gastrointestinal and mental health symptoms after COVID-19 show decreased tryptophan biosynthesis in their gut microbiome. Tryptophan is the precursor to serotonin, and lower tryptophan production correlated with both worsened GI symptoms and greater severity of mental health symptoms like anxiety and depression.¹² This provides a biochemical link between the gut and brain symptoms that so often travel together in post-COVID patients.

The autonomic nervous system, which controls involuntary functions like digestion, also takes a hit. COVID-19 patients can develop dysregulation of the autonomic nerves governing gut motility, leading to the hallmark IBS pattern of chronic abdominal pain, bloating, and erratic bowel habits persisting for months.¹³ This combination of disrupted serotonin signaling, altered microbiome chemistry, and autonomic dysfunction means the gut-brain axis gets hit from multiple directions at once.

Who Is Most Likely to Develop Post-COVID IBS?

Not everyone who catches COVID-19 develops lasting gut symptoms. Several risk factors have emerged from the research, and they paint a picture that involves both the severity of the initial infection and the patient’s baseline characteristics.

In the single-center study that found a 10.6% IBS rate, the strongest independent predictors after regression analysis were female sex, needing supplemental oxygen during the hospital stay, having gastrointestinal symptoms during the acute COVID-19 illness, and elevated procalcitonin levels, a marker of severe infection.³ Other research has identified loss of smell, loss of taste, and the presence of dyspeptic symptoms in the early months after infection as additional warning signs.¹⁴

Depression and anxiety play a surprisingly large role. One meta-analysis found that the pooled effect size for anxiety or depression in post-COVID IBS patients was roughly three times that of non-IBS patients, making psychological distress one of the strongest predictors identified.¹⁵ A 2025 review in Neurogastroenterology & Motility described how dyspnea and depression mediate the pathway from COVID-19 to IBS, emphasizing that post-COVID IBS fits a biopsychosocial model rather than a purely biological one.¹⁶

This does not mean the symptoms are “all in your head.” It means the brain and gut are so deeply interconnected that psychological stress amplifies gut inflammation, and gut inflammation worsens psychological symptoms. People who entered their COVID-19 infection already struggling with anxiety or depression, or who developed those symptoms during or after the illness, face a compounded risk.

What About Children?

The picture in pediatric patients is less clear and, so far, more reassuring than in adults. A large study published in JAMA Network Open examined gastrointestinal outcomes in children during the post-acute phase of COVID-19 and found that the risk of IBS was not statistically significant after adjusting for confounding variables.¹⁷ Another study following children who already had functional abdominal pain disorders found no significant difference in symptoms or quality of life between those who caught COVID-19 and those who did not.¹⁸

That said, children are not entirely unaffected. One survey-based study found increased somatic, emotional, and gastrointestinal symptom severity among children who tested positive for COVID-19, particularly among those who already had abdominal symptoms before testing. Children with a positive COVID-19 test had the highest symptom scores on nausea measures.¹⁹ The current evidence suggests COVID-19 may worsen existing gut symptoms in children rather than triggering new-onset IBS the way it does in adults, but more long-term pediatric data is needed.

Managing Post-COVID Gut Symptoms

There is no single treatment specifically approved for post-COVID IBS, and management currently follows the same general approach used for conventional IBS, tailored to whichever subtype a patient has. But the multifactorial nature of the condition means several therapeutic avenues are being explored.

Dietary adjustments: A low-FODMAP diet, which restricts certain fermentable carbohydrates, helps many conventional IBS patients and is a reasonable first step for post-COVID IBS. Keeping a food diary to identify personal triggers is practical and costs nothing.
Probiotics: Given the documented microbiome disruption after COVID-19, probiotics aimed at restoring short-chain fatty acid production have theoretical appeal, though high-quality trial data specific to post-COVID IBS are still limited.
Neuromodulators: Low-dose tricyclic antidepressants or SSRIs, already used for conventional IBS, may address both the gut motility issues and the serotonin signaling disruption seen after COVID-19. These are prescription medications that require a doctor’s guidance.
Addressing dysautonomia: For patients whose IBS symptoms come alongside other signs of autonomic dysfunction such as dizziness, rapid heart rate, or temperature regulation problems, treating the broader dysautonomia can help gut symptoms improve alongside.
Psychological support: Given how strongly anxiety and depression predict post-COVID IBS, cognitive behavioral therapy, gut-directed hypnotherapy, and stress management are not add-ons but core components of treatment.

Antivirals are also being studied as a potential approach. The logic is straightforward: if persistent viral material in the gut is driving ongoing immune activation, clearing that material might resolve symptoms. Research into antivirals, probiotics, neuromodulators, and dysautonomia treatments for long COVID gastrointestinal symptoms is ongoing.²⁰

Does the Genetic Evidence Support a Causal Link?

One question that hovers over all observational studies of post-COVID IBS is whether COVID-19 truly causes IBS or whether people who are already predisposed to gut problems are simply more likely to notice symptoms after an infection. Mendelian randomization studies attempt to address this by using genetic variants as proxies for exposure, which helps strip out some confounding factors that plague observational research.

A comprehensive Mendelian randomization study examining the causal relationship between COVID-19 infection, vaccination, and 20 digestive diseases found no strong causal link between COVID-19 and IBS based on genetic data.²¹ This does not invalidate the clinical observations, but it introduces an important nuance. The genetic architecture that makes someone susceptible to COVID-19 does not appear to overlap with the genetic architecture for IBS in a way that would produce a straightforward causal signal.

This could mean several things. It might mean the relationship is truly causal but mediated through environmental or immune pathways that genetic instruments do not capture well, such as viral persistence in gut tissue or microbiome disruption. It might mean that a subset of post-COVID IBS cases are genuinely caused by the infection while others represent unmasking of a pre-existing tendency. Or it might mean the association is partly driven by shared risk factors like stress, anxiety, and disrupted routine during the pandemic. The honest interpretation is that the mechanistic evidence for a direct viral-to-IBS pathway is compelling, but the population-level causal link remains more ambiguous than the case reports and observational studies alone would suggest.

The Decline Over Time and What It Means

One of the more hopeful findings in this literature is the time trend. As noted earlier, the pooled IBS incidence among COVID-19 patients drops from about 10% at six months to around 3% at twelve months.¹ This suggests the majority of post-COVID IBS cases are self-limiting, resolving within the first year as the gut’s immune environment normalizes, the microbiome rebuilds, and viral remnants are gradually cleared.

That is broadly consistent with what gastroenterologists see with post-infectious IBS from other causes. After bacterial gastroenteritis, for example, symptoms peak in the first few months and then gradually improve, though a fraction of patients remain symptomatic for years. The 3% figure at one year for post-COVID IBS is still meaningful, particularly when multiplied across the hundreds of millions of people who have had COVID-19 worldwide. Even a small percentage translates into a large absolute number of people living with a new chronic gut disorder. For those individuals, the condition is real, disruptive, and deserving of the same clinical attention as any other form of IBS.

If you developed new gut symptoms after a COVID-19 infection and they have persisted for three months or more, that pattern fits what researchers are calling post-COVID IBS. Bringing it up with a gastroenterologist is worthwhile, because the treatments for conventional IBS generally apply, and the earlier you address factors like microbiome disruption, serotonin signaling, and psychological distress, the better the chances of improvement.

1
European Journal of Gastroenterology & Hepatology. The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis
2
PubMed. Post-infection irritable bowel syndrome following Coronavirus disease-19: A systematic review and meta-analysis
3
European Journal of Gastroenterology & Hepatology. Incidence and predisposing factors for de novo post-COVID-19 irritable bowel syndrome
4
Gut. Post COVID-19 irritable bowel syndrome
5
BMJ. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis
6
PubMed Central. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges
7
PubMed Central. Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection
8
Nature Immunology. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
9
PubMed. Persistent Gut-Immune Axis dysregulation in long-term Post-COVID Syndrome: Insights from a prospective, observational, cross-sectional case-control study
10
PubMed Central. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19
11
PubMed Central. Single-cell gene expression links SARS-CoV-2 infection and gut serotonin
12
PubMed Central. Decreased Gut Microbiome Tryptophan Metabolism and Serotonergic Signaling in Patients With Persistent Mental Health and Gastrointestinal Symptoms After COVID-19
13
PubMed Central. COVID-19-induced gastrointestinal autonomic dysfunction: A systematic review
14
PubMed Central. Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study
15
European Journal of Gastroenterology & Hepatology. The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis
16
PubMed. Post-Coronavirus Disease (COVID)-19 Irritable Bowel Syndrome: What We’ve Learned So Far
17
JAMA Network Open. Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19
18
PubMed. Impact of Coronavirus disease 2019 pandemic in children with functional abdominal pain disorders: Data from long-term follow-up
19
PubMed. Somatic, emotional, and gastrointestinal symptom severity are increased among children and adolescents with COVID-19
20
PubMed. Gastrointestinal manifestations of long COVID
21
Virology Journal. Causal relationship between COVID-19, vaccination, and 20 digestive diseases: a comprehensive two-sample Mendelian randomization study